Figure 3

Analysis of nilotinib in a transgenic mouse model of terminal leukemia/lymphoma. (A), Five P190 Bcr/Abl transgenic mice were treated with 75 mg/kg nilotinib daily upon visible signs of lymphoma for a period of 30 days. This image shows one of the five mice treated with the drug. Arrows point to the dramatic reduction in the size of the lymph node swelling/lymphoma over a period of six days of treatment. (B), Survival after diagnosis of overt leukemia/lymphoma. Numbers to the left indicate individual identifiers of the transgenic mice. The arrow points to the first diagnosis of leukemia/lymphoma. The black line represents time to leukemia (days), the grey bars the period of treatment with nilotinib and the white bars time to death after no treatment. (C), Peripheral blood of two wild type (Wt) littermates; two overtly leukemic P190 Bcr/Abl transgenic mice before treatment and the same mice after 7 days of 75 mg/kg nilotinib treatment. Dead cells were excluded based on propidium iodide uptake and the analysis was restricted to living mononuclear cells by forward and side scatter gate settings. Antibodies are as indicated. (D), Percentage of peripheral blood cells that had cell surface expression of CD19 and high levels of AA4.1. Bars, ± SEM. Wild type, n = 3; preleukemic, n = 3; leukemic, n = 3; nilotinib-treated, n = 2.